THE ROLE OF INFLAMMATION IN OSTEOARTHRITIS: PATHOGENIC MECHANISMS AND MODERN TREATMENT STRATEGIES
Keywords:
Osteoarthritis, synovitis, inflammation, cartilage degradation, interleukin-1β, matrix metalloproteinase, subchondral bone, disease-modifying osteoarthritis drug.Abstract
Osteoarthritis (OA) has long been regarded as a passive, “wear-and-tear” degenerative disease of articular cartilage, but contemporary evidence reframes it as a low-grade chronic inflammatory disease affecting the whole joint organ — synovium, cartilage, and subchondral bone alike. This narrative review synthesizes current evidence on the inflammatory pathogenesis of OA and modern treatment strategies, drawing on the 2019 OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis and subsequent updates through 2025. Mechanical joint stress and chondrocyte senescence release damage-associated molecular patterns (DAMPs) that engage Toll-like receptors on synoviocytes and macrophages, activating NF-κB signaling and driving secretion of interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). These cytokines induce chondrocyte expression of matrix metalloproteinase-13 (MMP-13) and ADAMTS-5, degrading type II collagen and aggrecan, while low-grade synovitis, subchondral bone remodeling, osteophyte formation, and neoangiogenesis with nerve ingrowth close a self-perpetuating whole-joint inflammatory cycle that sustains both structural progression and pain. Modern management remains predominantly symptomatic: core non-pharmacologic treatment (exercise, education, and weight management) underlies all care, topical and oral anti-inflammatory agents and intra-articular corticosteroids or hyaluronic acid provide symptom control, and emerging disease-modifying osteoarthritis drugs (DMOADs) targeting inflammatory and catabolic pathways remain investigational, with no agent yet approved for disease modification. A mechanism-based understanding of inflammation in OA, combined with individualized, comorbidity-informed non-surgical management and judicious use of surgery in advanced disease, is central to reducing pain and disability, including within the healthcare system of Uzbekistan.
References
[1] Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589.
[2] Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220-233.
[3] Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013;21(1):16-21.
[4] Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(10):580-592.
[5] Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017;19(1):18.
[6] Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697-1707.
[7] Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci. 2010;1192:230-237.
[8] Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-1759.
[9] Wood MJ, Miller RE, Malfait AM. The genesis of pain in osteoarthritis: inflammation as a mediator of osteoarthritis pain. Clin Geriatr Med. 2022;38(2):221-238.
[10] Miller RE, Malfait AM, Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017;35 Suppl 107(5):85-87.
[11] Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and therapy. Osteoarthritis Cartilage. 2020;28(3):242-248.
[12] Latourte A, Kloppenburg M, Richette P. Emerging pharmaceutical therapies for osteoarthritis. Nat Rev Rheumatol. 2020;16(12):673-688.

